Earnings ·
biote Corp. reports Q3 revenue of $43.3M, a 9.6% decline from prior year
BTMDbiote Corp.
biote Corp. reported third-quarter 2026 financial results with total revenue of $43.3 million, down 9.6% from $48.0 million in the same period last year. Procedure revenue declined 15.1% to $28.9 million, while dietary supplements revenue grew 7.3% to $12.0 million. Gross profit margin was 67.7%, compared to 71.8% previously, impacted by a voluntary recall in January 2026 that increased reliance on lower-margin third-party pellets. Net income was $0.6 million with diluted earnings per share of $0.01, versus net income of $9.2 million and EPS of $0.22 in the prior-year quarter. Adjusted EBITDA fell to $5.1 million from $12.9 million. The company maintained its full-year 2026 guidance for revenue above $175 million and adjusted EBITDA above $25 million, noting that a return to growth is progressing more slowly than anticipated as it focuses on improving sales productivity and practitioner engagement. biote Corp. operates in the hormone optimization and healthy aging solutions industry.